The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | CLARITY-Gastric 02: Sone-Ve + capecitabine ± rilvegostomig in CLDN18.2+ GC/GEJC/EAC
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the rationale and trial design of the CLARITY-Gastric 02 (NCT07431281) trial, a Phase III study evaluating sonesitatug vedotin (Sone-Ve), a CLDN18.2-targeted antibody-drug conjugate (ADC), with capecitabine with or without rilvegostomig in CLDN18.2-positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma (GC/GEJC/EAC). The trial is based on encouraging results from a previous Phase III study, where Sone-Ve demonstrated significant overall survival improvement as a monotherapy in later-line therapy for CLDN18.2+ gastric cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
